Oryzon Genomics SA Net Assets
Oryzon Genomics SA net assets. Based on the latest financial reports, Oryzon Genomics SA (ORY) has net assets worth €117.85 Million EUR (≈ $137.78 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€144.52 Million ≈ $168.96 Million USD) and total liabilities (€26.68 Million ≈ $31.19 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Oryzon Genomics SA net asset momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €117.85 Million |
| % of Total Assets | 81.54% |
| Annual Growth Rate | 14.95% |
| 5-Year Change | 65.37% |
| 10-Year Change | 418.5% |
| Growth Volatility | 33.98 |
Net Assets of Oryzon Genomics SA (2011–2025)
Net assets of Oryzon Genomics SA from 2011 to 2025. This chart illustrates how Oryzon Genomics SA's net assets have evolved over time, based on quarterly financial data. See Oryzon Genomics SA (ORY) net asset quality to measure how much of total assets are equity-financed.
Annual Net Assets for Oryzon Genomics SA (2011–2025)
The table below shows the annual net assets of Oryzon Genomics SA from 2011 to 2025. For live market cap and overall valuation, see ORY market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €117.85 Million ≈ $137.78 Million |
+35.39% |
| 2024-12-31 | €87.04 Million ≈ $101.76 Million |
+6.44% |
| 2023-12-31 | €81.77 Million ≈ $95.60 Million |
+12.68% |
| 2022-12-31 | €72.57 Million ≈ $84.84 Million |
+1.84% |
| 2021-12-31 | €71.26 Million ≈ $83.31 Million |
-6.15% |
| 2020-12-31 | €75.93 Million ≈ $88.77 Million |
-5.10% |
| 2019-12-31 | €80.02 Million ≈ $93.55 Million |
+77.32% |
| 2018-12-31 | €45.13 Million ≈ $52.76 Million |
+31.06% |
| 2017-12-31 | €34.43 Million ≈ $40.25 Million |
+51.49% |
| 2016-12-31 | €22.73 Million ≈ $26.57 Million |
-17.63% |
| 2015-12-31 | €27.59 Million ≈ $32.26 Million |
+98.61% |
| 2014-12-31 | €13.89 Million ≈ $16.24 Million |
-5.67% |
| 2013-12-31 | €14.73 Million ≈ $17.22 Million |
-10.34% |
| 2012-12-31 | €16.43 Million ≈ $19.20 Million |
-1.97% |
| 2011-12-31 | €16.76 Million ≈ $19.59 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Oryzon Genomics SA's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2081215200.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Oryzon Genomics SA Net Assets Breakdown (December 2025)
Oryzon Genomics SA net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | €3.99 Million | 3.79% |
| Other Comprehensive Income | €-4.09 Million | -3.88% |
| Other Components | €126.35 Million | 119.82% |
| Total Equity | €105.45 Million | 100.00% |
Oryzon Genomics SA Competitors by Market Cap
The table below lists competitors of Oryzon Genomics SA ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Etteplan Oyj
HE:ETTE
|
$211.36 Million |
|
Armac Locacao Logistica
SA:ARML3
|
$211.44 Million |
|
Air Asia Co Ltd
TW:2630
|
$211.48 Million |
|
D2L Inc
TO:DTOL
|
$211.51 Million |
|
BAIRONG INC.CL.B -00002
F:6B5
|
$211.30 Million |
|
Wuhan Golden Laser Co Ltd
SHE:300220
|
$211.30 Million |
|
Archimedes Tech SPAC Partners II Co. Unit
NASDAQ:ATIIU
|
$211.27 Million |
|
ES Cube Co. Ltd
KQ:050120
|
$211.20 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Oryzon Genomics SA's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 87,042,434 to 105,448,753, a change of 18,406,319 (21.1%).
- Net loss of 2,605,469 reduced equity.
- New share issuances of 28,654,218 increased equity.
- Other comprehensive income decreased equity by 8,444,446.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-2.61 Million | -2.47% |
| Share Issuances | €28.65 Million | +27.17% |
| Other Comprehensive Income | €-8.44 Million | -8.01% |
| Other Changes | €802.02K | +0.76% |
| Total Change | €- | 21.15% |
Book Value vs Market Value Analysis
This analysis compares Oryzon Genomics SA's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.64x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 3.67x to 1.64x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | €0.63 | €2.33 | x |
| 2014-12-31 | €0.49 | €2.33 | x |
| 2015-12-31 | €1.00 | €2.33 | x |
| 2016-12-31 | €0.82 | €2.33 | x |
| 2017-12-31 | €1.06 | €2.33 | x |
| 2018-12-31 | €1.17 | €2.33 | x |
| 2019-12-31 | €1.16 | €2.33 | x |
| 2020-12-31 | €1.44 | €2.33 | x |
| 2021-12-31 | €1.35 | €2.33 | x |
| 2022-12-31 | €1.29 | €2.33 | x |
| 2023-12-31 | €1.34 | €2.33 | x |
| 2024-12-31 | €1.35 | €2.33 | x |
| 2025-12-31 | €1.42 | €2.33 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Oryzon Genomics SA utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -2.47%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.37x
- Recent ROE (-2.47%) is above the historical average (-3.52%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | -14.66% | -91.48% | 0.08x | 1.95x | €-3.63 Million |
| 2014 | 47.87% | 50.69% | 0.50x | 1.88x | €5.26 Million |
| 2015 | -3.60% | -23.32% | 0.10x | 1.48x | €-3.75 Million |
| 2016 | -23.97% | -740.91% | 0.01x | 2.19x | €-7.72 Million |
| 2017 | -15.09% | -31000.95% | 0.00x | 1.77x | €-8.64 Million |
| 2018 | -2.61% | -17.36% | 0.10x | 1.49x | €-5.69 Million |
| 2019 | -6.03% | -35.85% | 0.13x | 1.31x | €-9.80 Million |
| 2020 | -4.48% | -35.71% | 0.10x | 1.24x | €-10.99 Million |
| 2021 | -6.58% | -44.15% | 0.11x | 1.34x | €-11.81 Million |
| 2022 | -5.83% | -26.95% | 0.15x | 1.43x | €-11.49 Million |
| 2023 | -4.10% | -23.63% | 0.13x | 1.31x | €-11.53 Million |
| 2024 | -4.21% | -49.80% | 0.07x | 1.25x | €-12.37 Million |
| 2025 | -2.47% | 0.00% | 0.00x | 1.37x | €-13.15 Million |
Industry Comparison
This section compares Oryzon Genomics SA's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $63,092,318
- Average return on equity (ROE) among peers: 0.40%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Oryzon Genomics SA (ORY) | €117.85 Million | -14.66% | 0.23x | $211.33 Million |
| Atrys Health SL (ATRY) | $75.33 Million | -7.37% | 1.33x | $204.95 Million |
| Biotechnology Assets S.A. (BST) | $6.53 Million | 24.09% | 1.54x | $13.52 Million |
| Pharma Mar S.A. (PHM) | $166.90 Million | -21.12% | 0.63x | $1.32 Billion |
| Vytrus Biotech S.A. (VYT) | $3.61 Million | 6.01% | 0.72x | $120.39 Million |
About Oryzon Genomics SA
Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS (central nervous system), oncology, and hematology disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-… Read more